DBVT - Here's Why DBV Technologies Shares Jumped Higher Today
Shares of DBV Technologies (NASDAQ: DBVT) are up 11% at 12:40 p.m. EST on positive long-term data for the biotech's peanut allergy medication Viaskin Peanut.
Children in the phase 3 Pepites clinical trial were able to continue on the drug in an extension study called People. After three years of treatment, 75.9% of patients had increased their eliciting dose (ED) -- the amount of peanut protein a patient can take before having an allergic reaction -- and 51.8% of patients reached an ED of at least 1,000 mg peanut protein. Only 40.4% of the patients had reached that threshold after 12 months, suggesting that longer doses can help some patients gain greater immunity.
DBV Technologies also reported some data suggesting the drug has a lasting effect. Patients who reached the 1,000 mg threshold were taken off of Viaskin Peanut and retested two months later, when 77.8% of the 18 children continued to tolerate 1,000 mg of peanut protein.